These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1127 related articles for article (PubMed ID: 1386251)

  • 1. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
    Tuttle TM; Inge TH; McCrady CM; Bethke KP; Bear HD
    J Immunother (1991); 1992 Jul; 12(1):32-40. PubMed ID: 1386251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phorbol dibutyrate plus ionomycin improves the generation of cytotoxic T cells from draining lymph nodes of patients with advanced head and neck cancer.
    McGrath PC; Hamby LS; Freeman JW
    Am J Surg; 1992 Dec; 164(6):610-4. PubMed ID: 1463110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phorbol dibutyrate and ionomycin improve murine effector cell cytotoxicity.
    Hamby LS; Freeman JW; McGrath PC
    J Surg Res; 1993 Feb; 54(2):115-21. PubMed ID: 8479168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
    Tuttle TM; Inge TH; Lind DS; Bear HD
    Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
    Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bryostatin 1 activates T cells that have antitumor activity.
    Tuttle TM; Inge TH; Wirt CP; Frank JL; McCrady CM; Bear HD
    J Immunother (1991); 1992 Aug; 12(2):75-81. PubMed ID: 1504056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancers.
    Hoover SK; Frank JL; McCrady C; McKinnon JG; Bear HD
    J Surg Oncol; 1991 Feb; 46(2):117-24. PubMed ID: 1825123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.
    Tuttle TM; Fleming MD; Hogg PS; Inge TH; Bear HD
    Ann Surg Oncol; 1994 Jan; 1(1):53-8. PubMed ID: 7834429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes.
    McKinnon JG; Hoover SK; Inge TH; Bear HD
    Cancer Immunol Immunother; 1990; 32(1):38-44. PubMed ID: 2126983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bryostatin 1-activated T cells can traffic and mediate tumor regression.
    Tuttle TM; Bethke KP; Inge TH; McCrady CW; Pettit GR; Bear HD
    J Surg Res; 1992 Jun; 52(6):543-8. PubMed ID: 1528028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro.
    Haynes C; Graham L; Bear HD
    Methods Cell Biol; 2024; 183():355-380. PubMed ID: 38548419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
    Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro cytolytic activity of lymphocytes from tumor-draining lymph nodes is associated with increased numbers of CD8+ cells and increased cytokine production.
    Holley D; Freeman J; Hamby L; Mattingly C; McGrath PC
    J Surg Res; 1995 Jan; 58(1):33-7. PubMed ID: 7830403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K; Chang AE; Shu S
    Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.